Similar Papers

Paper Title
Journal
Date
Author
Severe asthma in the US population and eligibility for mAb therapy
Ayobami Akenroye ... Corinne Keet
Journal of Allergy and Clinical Immunology | VOL. 145
Ayobami Akenroye, et. al.Ayobami Akenroye ... Corinne Keet
19 Dec 2019
Indirect treatment comparisons and biologics
David Mauger ... Andrea J Apter
Journal of Allergy and Clinical Immunology | VOL. 143
David Mauger, et. al.David Mauger ... Andrea J Apter
01 Jan 2019
Organization of biological therapy for patients with severe eosinophilic bronchial asthma in the Krasnoyarsk region
I V Demko ... E A Sobko
PULMONOLOGIYA | VOL. 33
I V Demko, et. al.I V Demko ... E A Sobko
11 Feb 2023
Update on immunogenicity in severe asthma: Experience with mepolizumab
Hector G Ortega ... Gerald J Gleich
The Journal of Allergy and Clinical Immunology: In Practice | VOL. 7
Hector G Ortega, et. al.Hector G Ortega ... Gerald J Gleich
05 Apr 2019
View more papers

More From: Immunotherapy

Paper Title
Journal
Date
Author
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.
Ozkan Alan ... Nil Molinas Mandel
Immunotherapy | VOL. -
Ozkan Alan, et. al.Ozkan Alan ... Nil Molinas Mandel
15 Jan 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).
Stanley Szefler ... Andrew Blauvelt
Immunotherapy | VOL. -
Stanley Szefler, et. al.Stanley Szefler ... Andrew Blauvelt
09 Jan 2025
Plain language summary of the SHAMAL study in patients with severe eosinophilic asthma treated with benralizumab.
David J Jackson ... Stephanie Korn
Immunotherapy | VOL. -
David J Jackson, et. al.David J Jackson ... Stephanie Korn
09 Jan 2025
Anakinra in relapsing polychondritis: a case report and review of the literature.
Syed B Ali ... Anthony Smith
Immunotherapy | VOL. -
Syed B Ali, et. al.Syed B Ali ... Anthony Smith
20 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.